ClinicalTrials.gg
RecruitingNCT04935619Updated Feb 24, 2025

Extended Effects of Cannabis Abstinence on Clinical Symptoms and Cognition in Depression

An interventional study of Contingency Reinforcement and Non-Contingency Reinforcement in Cannabis Use, Major Depressive Disorder and Cognitive Impairment, sponsored by Centre for Addiction and Mental Health. Recruiting at 1 site in Canada. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Centre for Addiction and Mental Health · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2021; still recruiting 5 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
52
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health — 10 open to participants now, 13 under way, none of them phase 3. Depressive Disorder, Major · Centre for Addiction and Mental Health.

Planned enrollment
29th of 44
52 · median 72
Started
2021
with 3 others
No phase
36 of 48
6 open now
Primary completion
2027-06
later than 7 of 12 live
Registered
35th of 48
by date

Among the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, this one is the 29th largest by planned enrollment of the 44 interventional ones that give a count, is one of 4 that started in 2021, is one of 36 with no phase, reaches primary completion later than 7 of the 12 other live ones, and was the 35th registered.

Depressive Disorder, Major

3,051 studies on the registry are indexed under Depressive Disorder, Major; 596 are open to participants now.

Browse Depressive Disorder, Major studies →

Open to participants now

10 of the 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health are open now, in 1 country. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 10 open studies →

Where they have run

Who these studies take

Of the 419 Depressive Disorder, Major studies recruiting now, 93 (22%) set no upper age limit and 299 (71%) stop at 75 or younger; 55 take children under 18; 100 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 48 studies in Depressive Disorder, Major by Centre for Addiction and Mental Health, or all of them as a file.
02

Study summary

The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. Most studies of cannabis use in MDD are cross-sectional in design, and therefore causal relationships are unclear. This study investigates the effects of cannabis abstinence over a 28-day period in patients with MDD with co-occurring CUD using a randomized controlled design, namely contingent reinforcement.

Read the detailed description

The prevalence of major depressive disorder (MDD) is \~5.0%, and rates of co-occurring SUDs in these patients approach 40-50%. Specifically, rates of co-morbid cannabis use disorder (CUD) in patients with MDD are elevated 2-3 fold compared to 2.9% in the general population, and is associated with poorer treatment outcomes and impaired cognitive and psychosocial functioning in comparison to MDD patients without CUD. To date, most studies of cannabis use in MDD were cross-sectional in design, and therefore causal relationships are unclear. The investigators previous studies in cannabis dependent patients with schizophrenia suggest that extended cannabis abstinence (up to 28 days) using contingent reinforcement is associated with improvements in specific areas of cognition (e.g. verbal learning and memory) and depressive symptoms. A more recent study using an open-label design demonstrated that 28 days of cannabis abstinence improves depressive symptoms and anhedonia in participants (N=11) with co-occurring MDD and CUD.

The investigators propose a controlled cannabis abstinence paradigm in patients with co-morbid MDD and CUD (N=52) to further investigate these findings. Stabilized MDD patients with moderate to severe CUD will be randomly assigned to one of two groups: 1) A contingent reinforcement (CR) intervention (n=26); 2) a non-contingent reinforcement (NCR) intervention (n=26), which will serve as a time and non-abstinence control. In the CR group, subjects achieving biochemically-verified cannabis abstinence at study endpoint (Day 28) will receive a $300 contingent payment; participants in the NCR group will not receive this contingent payment. The primary outcomes are: 1) cannabis abstinence rates at Day 28 in CR versus NCR groups; 2) changes in mood (depressive), anxiety and sleep symptoms over the 28-day assessment period. Secondary outcomes include cognition.

03

Conditions studied

  • Cannabis Use
  • Major Depressive Disorder
  • Cognitive Impairment

Keywords

  • cannabis
  • substance abuse
  • depression
  • anxiety
  • contingency reinforcement
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All participants must be between the ages 18-55
  • Meet SCID for diagnostic criteria for cannabis use disorder, moderate to severe
  • Meet SCID for DSM-5 diagnostic criteria for Major Depressive Disorder
  • Be an outpatient receiving a stable dose of antidepressant medication for at least three months (to ensure stability of depressive symptoms
  • Have a Hamilton Depression Rating Scale (HDRS-17) at baseline assessment in the range of 12-25..
  • Have a Full-Scale IQ ≥ 80 as determined by the WTAR
  • Be a non-treatment seeking cannabis user
  • Evidence of sufficient motivation and effort as measured by a Test of Memory Malingering (TOMM) score ≥ 45.

Exclusion criteria

Exclusion Criteria:

  • Meets criteria for substance use disorder of alcohol or other illicit substances within the past 6 months (with the exception of cannabis, nicotine, or caffeine)
  • Positive urine screen for illicit substances other than cannabis, nicotine, or caffeine
  • Current suicidal or homicidal ideation
  • Psychotic disorder diagnosis (e.g. schizoaffective disorder, major depression with psychotic features) as determined by the SCID
  • Treatment seeking for cannabis use
  • Meet SCID for diagnostic criteria for Bipolar Disorder
  • Head Injury> 5 minutes LOC
  • Exceed upper and lower cut-offs on HSRD-17 (See Inclusion Criteria)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
52 participants (estimated)

Study arms

  • Other
    Non-Contingency Reinforcement Group

    Subjects assigned to the NCR group with self-reported abstinence verified by urinary THC-COOH level \<20 ng/ml will not receive contingency monetary reinforcement at Day 28 of the study.

    Behavioral: Non-Contingency Reinforcement

  • Experimental
    Contingency Reinforcement Group

    Subjects assigned to the CR group with self-reported abstinence verified by urinary THC-COOH level \<20 ng/ml will receive contingency monetary reinforcement at Day 28 of the study.

    Behavioral: Contingency Reinforcement

Interventions

  • BehavioralContingency Reinforcement

    Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.

  • BehavioralNon-Contingency Reinforcement

    Subjects will be randomly assigned on a 1:1 ratio to either the Contingency Reinforcement or Non-Contingency Reinforcement Intervention prior to their in-person screening visit.

06

What researchers measure

Primary outcomes

  1. Changes in Depressive Symptomology from Baseline to Week 4

    The Hamilton Depression Rating Scale will be administered to assess severity of depressive symptoms. \[Min score = 0, Max score = 52; Higher scores evince more severe symptomology\]

    Time frame: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]

  2. Changes in Anxious Symptomology from Baseline to Week 4

    The Beck Anxiety Inventory will be administered to assess severity of anxiety symptoms \[Min score = 0, Max score = 63; Higher scores evince more severe symptomology\].

    Time frame: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]

  3. Changes in Sleep Symptomology from Baseline to Week 4

    The Pittsburgh Sleep Quality Index will be administered weekly to examine quality of sleep and other sleep disturbances \[Min score = 0, Max score = 21; Higher scores evince more severe symptomology\].

    Time frame: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]

  4. Changes in Anhedonia from Baseline to Week 4

    The Snaith-Hamilton Pleasure Scale will be administered weekly to measure changes in anhedonia \[Min score = 0, Max score = 14; Higher scores evince more severe symptomology\].

    Time frame: [Time Frame: Weekly (Day 0, Day 7, Day 14, Day 21, Day 28)]

Secondary outcomes

  1. Changes in Verbal Learning and Memory

    The Hopkins Verbal Learning Test will be administered to investigate this cognitive domain.

    Time frame: Day 0 and Day 28

  2. Changes in Attention and Visual Search

    The Trail Making Test will be administered to investigate these cognitive domains

    Time frame: Day 0 and Day 28

  3. Changes in Working Memory

    The Digit Span test will be administered to investigate this cognitive domain.

    Time frame: Day 0 and Day 28

  4. Changes in Sustained Attention

    The Continuous Performance Test will be administered to investigate this cognitive domain

    Time frame: Day 0 and Day 28

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2021 (actual). Primary completion is estimated for Jun 2027, 71 months after the start.

Of 654 non-industry interventional studies with no phase under Depressive Disorder, Major, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 55. This study's planned 71 months is above that.

Counting every sponsor, half of 694 studies reached it within 33 months; a quarter within 17 and three quarters within 55.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2021
First posted
Jun 23, 2021
StartActual
Jul 21, 2021
Primary completionEst.
Jun 30, 2027
CompletionEst.
Aug 31, 2027
Last update
Feb 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04935619
Responsible party
Sponsor
First posted
Jun 23, 2021
Start date
Jul 21, 2021
Primary completion
Jun 30, 2027 (estimated)
Completion
Aug 31, 2027 (estimated)
Last update
Feb 24, 2025

Study contacts

Maryam Sorkhou, HBSc
Contact
maryam.sorkhou@mail.utoronto.ca
4165358501 ext. 36225
Tony P George, MD., FRCPC
principal investigator · CAMH

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion